B0F.F PAXMAN AB
- Market cap
- EUR 128M
- P/E
- -
- P/B
- 3.44x
- ROE
- 1.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is B0F.F undervalued?
Graham numberThe Graham number of PAXMAN AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PAXMAN AB fundamental analysis
No fundamental analysis for PAXMAN AB yet.
PAXMAN AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PAXMAN AB
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Ka…
Full company profilePAXMAN AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PAXMAN AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 96.2M | 146M | 210M | 253M | 313M | 389M |
| Gross Profit | 64.5M | 101M | 146M | 175M | 209M | 262M |
| Operating Income | -10.6M | -1.24M | 12.6M | 33.5M | 4.26M | 8.01M |
| EBITDA | - | 16.2M | 31.2M | 58.9M | 29.9M | 48.8M |
| Net Income | -12.8M | -10.3M | 8.33M | 40.2M | -16.7M | 4.88M |
| EPS | -0.67 | -0.54 | 0.44 | 2.11 | -0.72 | 0.21 |
| Balance Sheet | ||||||
| Total Assets | 166M | 174M | 167M | 227M | 479M | 488M |
| Total Liabilities | 40.6M | 59.8M | 44.5M | 63.2M | 74.0M | 71.3M |
| Shareholders' Equity | 126M | 114M | 123M | 164M | 405M | 417M |
| Cash & Short-term Investments | 72.3M | 38.1M | 25.0M | 40.3M | 121M | 106M |
| Cash Flow | ||||||
| Operating Cash Flow | -4.14M | 2.69M | 15.6M | 32.6M | 7.39M | -10.9M |
| Capital Expenditure | 23.8M | 35.7M | 25.3M | 17.2M | 23.5M | 17.8M |
| Free Cash Flow | -27.9M | -33.0M | -9.70M | 15.4M | -16.1M | -28.7M |
| Ratios | ||||||
| ROE | -10.2% | -9.0% | 6.8% | 24.5% | -4.1% | 1.2% |
| ROA | -7.7% | -5.9% | 5.0% | 17.7% | -3.5% | 1.0% |
| Net Profit Margin | -13.3% | -7.1% | 4.0% | 15.9% | -5.3% | 1.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PAXMAN AB dividends
PAXMAN AB has not paid dividends in the last 5 fiscal years.
Who owns PAXMAN AB
- Insiders 35.51%
- Institutions 24.53%
- Public & others 39.96%
- Shares outstanding 23.3M
- Free float 16.6M
PAXMAN AB company profile
- Company name
- PAXMAN AB
- Ticker
- B0F.F
- ISIN
- SE0009806284
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 151
- Fiscal year end
- December
- Address
- Pirgatan 13, Karlshamn, Sweden, 374 35
- Website
- paxmanscalpcooling.com
About PAXMAN AB
Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.
PAXMAN AB management
10- Mr. Richard Paxman O.B.E.CEO & Director · born 1983
- Ms. Emelie GustafssonChief Financial Officer · born 1980
- Ms. Alexandra SheldrakeHead of Operations · born 1985
- Dr. Simon TaylorTechnical Manager
- Ms. Louise Aspey-SmithHead of Brand & Marketing Manager
- Ms. Liza HirstEA to CEO & Head of HR · born 1974
- Ms. Claire PaxmanHead of Clinical Practice & Education · born 1978
- Mr. Patrick BurkeHead of Research and Development · born 1959
- Ms. Emma ThornhillGroup Finance Director · born 1985
- Mr. Stuart RowlingHead of UK Sales & Training · born 1982